Skip to main content
. 2025 May 24;23(5):869–883. doi: 10.1007/s40258-025-00977-6

Table 11.

Major cardiovascular events relative risk reduction – model results compared with RCTs

Model – entire cohort (lifetime) RCTs (meta-analyses from evidence review – various follow-up points)
Ezetimibe −7% −6%
Inclisiran −16% −26%
PCSK9 inhibitors −17% −17%